PURA - Analyst Anticipates Puration Inc Sales To Reach $3 Million In 2019 With Hemp-Based CBD Market Growing To $1.9 Billion
November 20 2018 - 8:49AM
InvestorsHub NewsWire
Dallas, TX --
November 20, 2018 -- InvestorsHub NewsWire -- Puration, Inc.
(USOTC:
PURA) today announced that Goldman Small Cap Research issued a
research update on the Company. The report includes a
'speculative-buy' rating with a target price-per-share
of $0.25. The report previews upcoming milestones and
provides an analysis of Puration’s recent financial results and new
initiatives. To view the update report, along with disclosures and
disclaimers, visit http://www.GoldmanResearch.com or view the
report on the company’s website at https://www.purationinc.com/goldman-3q2018-update.
Puration
Goldman Small Cap Research Report
Highlights
Puration, Inc.
is a leading Texas-based, CBD-infused beverage provider. The
Company’s flagship product, EVERx, which was introduced in 2017,
targets the sports nutrition market. Puration plans to introduce
new beverages organically in addition to making targeted
acquisitions. The Company recently spun-off its cannabis
cultivation segment to focus its efforts exclusively on its
high-growth core CBD-infused beverage business.
According to
Hemp Business Journal, the overall hemp-based CBD market is
forecast to grow from $820 million in 2017 to $1.9 billion in 2022
and given that the market remains fragmented, fast-growing PURA is
well positioned to capture market share very
quickly.
In the
Opportunity Research update, analyst Rob Goldman discusses the
Company’s strong financials, and exciting upcoming opportunities
that lie ahead.
Goldman noted,
“PURA announced very strong 3Q18 results and the best is yet to
come. As a result, we believe that current prices represent a
terrific entry point for opportunistic investors. Moreover, we
expect PURA could return to its 52-week high of $0.25 early next
year, on the heels of products with new, upgraded packaging which
will begin reaching stores next week. PURA’s new package form is
priced at a convenient $20 per 4-pack. Management believes that
this new form will take sales to the next level.”
“We believe our forecasts are conservative.
For 2019, we estimate sales will reach $3M, with operating profit
of $800,000. It should be noted that these figures exclude any
contributions from new products which are likely to be introduced
in the coming weeks. Separately, an under
the radar near-term catalyst is the pending dividend related to the
transaction with Nouveau Life Pharmaceuticals, (OTC
- NOUV). NOUV formally declared a 1:5 stock dividend whereby
NOUV common will be issued to PURA shareholders at a ratio of one
NOUV common share for every five shares of PURA held on the yet to
be determined date of record. Although this event is not
factored into the current stock price, we believe these shares
could rise ahead of the record date
announcement.“
About
Goldman Small Cap Research: Founded in 2009 by former
Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman
Small Cap Research produces sponsored and non-sponsored small cap
and microcap stock research reports, articles, stock market blogs,
and popular investment newsletters.
Goldman Small
Cap Research is not in any way affiliated with Goldman Sachs &
Co.
This press
release contains excerpts of our most recently published sponsored
company research report on Alternet Systems, Inc. which carries a
rating and a price target. The information used and
statements of fact made have been obtained from sources considered
reliable but we neither guarantee nor represent the completeness or
accuracy. Goldman Small Cap Research
relied solely upon information derived from Puration, Inc. (“the
Company”) authorized press releases or legal disclosures made in
its filings with the U.S. Securities and Exchange Commission
http://www.sec.gov.
Separate from the factual content of our report about
the Company, we may from time to time include our own opinions
about the Company, its business, markets and opportunities. Any
opinions we may offer about the Company are solely our own, and are
made in reliance upon our rights under the First Amendment to the
U.S. Constitution, and are provided solely for the general
opinionated discussion of our readers. Our opinions should not be
considered to be complete, precise, accurate, or current investment
advice. Statements herein may contain forward-looking statements
and are subject to significant risks and uncertainties affecting
results.
A Goldman
Small Cap Research report, update, newsletter, article, trading
alert, corporate profile, or press release is not intended as an
offering, recommendation, or a solicitation of an offer to buy or
sell the securities mentioned or discussed is to be used for informational purposes
only. Please read all associated full disclosures,
disclaimers, and analyst background on our website before
investing. Neither Goldman Small Cap Research nor its parent is a
registered investment adviser or broker-dealer with FINRA or any
other regulatory agency. To download this research report or any of
our research, view our disclosures and disclaimers, or for more
information, visit www.goldmanresearch.com. Goldman Small Cap
Research was compensated $5500 by the Company for research and
distribution services. GSCR was not compensated for the production
and distribution of this update.
About
Puration, Inc. (OTC
- PURA) Puration, Inc. is a leading Texas-based,
CBD-infused beverage provider. The Company’s flagship product,
EVERx, which was introduced in 2017, targets the sports nutrition
market. Puration plans to introduce new beverages as well as grow
it product portfolio organically as well as through targeted
acquisitions. As of October 2018, the Company was set to spin off
its cannabis cultivation segment to focus its efforts exclusively
on its high-growth core CBD-infused beverage
business.
For more
information, please visit: www.PurationInc.com
Goldman Small
Cap Research
Rob Goldman,
Analyst
410-609-7100
rob@goldmanresearch.com
Puration,
Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Sep 2023 to Sep 2024